Drugs /

eicosapentaenoic acid

Back to Drugs List

Overview

NCI Definition [1]:
An essential, polyunsaturated, 20-carbon omega-3 fatty acid with anti-inflammatory and potential antineoplastic and chemopreventive activities. Eicosapentaenoic acid (EPA) may activate caspase 3, resulting in apoptosis in susceptible tumor cell populations. In addition, this agent may inhibit cyclooxygenase-2 (COX-2), resulting in inhibition of prostaglandin synthesis and prostaglandin-mediated inflammatory processes.

Clinical Trials

View Clinical Trials for eicosapentaenoic acid

Eicosapentaenoic acid has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating eicosapentaenoic acid, 1 is phase 1/phase 2 (0 open).

BCR-ABL1 Fusion and t(9;22)(q34;q11) are the most frequent biomarker inclusion criteria for eicosapentaenoic acid clinical trials.

Chronic myeloid leukemia is the most common disease being investigated in eicosapentaenoic acid clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Eicosapentaenoic Acid
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating eicosapentaenoic acid and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
icosapent, epa - eicosapentaenoic acid, timnodonic acid, eicosapentaenoic acid (substance), all cis-5,8,11,14,17-eicosapentaenoic acid, eicosapentaenoic acid, eicosapentaenoic acid, epa, omega-3-eicosapentaenoic acid, (5z,8z,11z,14z,17z)-5,8,11,14,17-eicosapentaenoic acid, all cis-5,8,11,14,17-eicosapentaenoic acid, cis, cis, cis, cis, cis-eicosa-5,8,11,14,17-pentaenoic acid, all-cis-5,8,11,14,17-eicosapentaenoic acid, 5,8,11,14,17-eicosapentaenoic acid, icosapentaenoic acid, cis-5,8,11,14,17-epa, cis-5,8,11,14,17-eicosapentaenoic acid, timnodonic acid, eicosapentaenoic acid, fatty acid 20:5, eicosapentanoic acid, 5,8,11,14,17-icosapentaenoic acid, all-cis-icosa-5,8,11,14,17-pentaenoic acid, 5,8,11,14,17-eicosapentaenoic acid, omega 3 eicosapentaenoic acid, icosapentaenoic acid, cis-delta(5,8,11,14,17)-eicosapentaenoic acid, icosapento, (5z,8z,11z,14z,17z)-eicosapentaenoic acid, icosapentaenoic acid, (5z,8z,11z,14z,17z)-icosapentaenoic acid, all-cis-5,8,11,14,17-icosapentaenoic acid, 5,8,11,14,17-eicosapentaenoic acid, acid, eicosapentanoic, eicosapentaenoic acid [chemical/ingredient], 5,8,11,14,17-icosapentaenoic acid, eicosapentaenoic acid 05 08 11 14 17, timnodonic acid, (all-z)-5,8,11,14,17-eicosapentaenoic acid, ipa, icosapentum, (5z,8z,11z,14z,17z)-eicosapentaenoate
NCIT ID [1]:
C67080
SNOMED ID [1]:
F-63363

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.